beeldscherm schreef op 27 januari 2017 14:42:
Pharma seeks orphan designation for more drugs than ever before
JANUARY 26, 2017
In recent years, orphan drugs have become a pharmaceutical gold mine — and the latest data underscore the unbridled enthusiasm among drug makers.
Orphan drugs become big business
Investors are drawn to the low-volume, high-margin model
Orphan drugs might target small groups of patients, but they are increasingly big business.
Pharmaceutical companies, from tiny biotech start-ups to Shire, the London-listed group with a market capitalisation of more than £30bn, are focusing on drugs for orphan diseases, lured by regulatory incentives and a low-volume, high-margin business model.
Ever since the introduction of the US Orphan Drug Act 32 years ago, developing medicines for rare disease has become the so-called “Goldilocks option” for some pharma companies.
Groups selling orphan drugs are granted seven years of market exclusivity (against five years for most medicines), along with generous tax credits. Because they target diseases that do not already have treatments, they also tend to benefit from other regulatory initiatives designed to get drugs to market more quickly.
dus een Overname v Pharming is in the making..? hoop het niet.